» Articles » PMID: 20726711

Fractionated Radiation Therapy Can Induce a Molecular Profile for Therapeutic Targeting

Overview
Journal Radiat Res
Specialties Genetics
Radiology
Date 2010 Aug 24
PMID 20726711
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

To examine the possibility of using fractionated radiation in a unique way with molecular targeted therapy, gene expression profiles of prostate carcinoma cells treated with 10 Gy radiation administered either as a single dose or as fractions of 2 Gy × 5 and 1 Gy × 10 were examined by microarray analysis. Compared to the single dose, the fractionated irradiation resulted in significant increases in differentially expressed genes in both cell lines, with more robust changes in PC3 cells than in DU145 cells. The differentially expressed genes (>twofold change; P < 0.05) were clustered and their ontological annotations evaluated. In PC3 cells genes regulating immune and stress response, cell cycle and apoptosis were significantly up-regulated by multifractionated radiation compared to single-dose radiation. Ingenuity Pathway Analysis (IPA) of the differentially expressed genes revealed that immune response and cardiovascular genes were in the top functional category in PC3 cells and cell-to-cell signaling in DU145 cells. RT-PCR analysis showed that a flexure point for gene expression occurred at the 6th-8th fraction and AKT inhibitor perifosine produced enhanced cell killing after 1 Gy × 8 fractionated radiation in PC3 and DU145 cells compared to single dose. This study suggests that fractionated radiation may be a uniquely exploitable, non-oncogene-addiction stress pathway for molecular therapeutic targeting.

Citing Articles

The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.

Yang L, Cui X, Wu F, Chi Z, Xiao L, Wang X Front Immunol. 2024; 15:1392499.

PMID: 38846948 PMC: 11154111. DOI: 10.3389/fimmu.2024.1392499.


vaccination caused by diverse irradiation-driven cell death programs.

Wang Y, Li Y, Yang Y, Swift M, Zhang Z, Wu S Theranostics. 2024; 14(3):1147-1167.

PMID: 38323315 PMC: 10845208. DOI: 10.7150/thno.86004.


Emerging evidence for adapting radiotherapy to immunotherapy.

Galluzzi L, Aryankalayil M, Coleman C, Formenti S Nat Rev Clin Oncol. 2023; 20(8):543-557.

PMID: 37280366 DOI: 10.1038/s41571-023-00782-x.


The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers.

Saidian A, Dolendo I, Sharabi A, Stewart T, Rose B, McKay R Cancers (Basel). 2023; 15(1).

PMID: 36612124 PMC: 9818005. DOI: 10.3390/cancers15010127.


Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.

Bardoscia L, Pasinetti N, Triggiani L, Cozzi S, Sardaro A Front Pharmacol. 2021; 12:746853.

PMID: 34790123 PMC: 8591245. DOI: 10.3389/fphar.2021.746853.